FOXO4-DRI
FOXO4-D-Retro-Inverso peptide
FOXO4-DRI (FOXO4-D-Retro-Inverso peptide) is a longevity & bioregulators research compound. Senolytic — disrupts the FOXO4–p53 interaction so senescent 'zombie' cells self-destruct, clearing them from tissue.
FOXO4-DRI quick facts
| Reported research dose | 5mg |
| Route | Subq |
| Frequency | 1x Daily · 3 Days |
| Half-life | ~6-12 hrs |
| Forms | Injectable |
| Evidence level | Animal |
Senolytics are run in short pulses, not continuously. Genuinely cutting-edge, genuinely early.
How FOXO4-DRI works
Senolytic — disrupts the FOXO4–p53 interaction so senescent 'zombie' cells self-destruct, clearing them from tissue.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get FOXO4-DRI
Buy FOXO4-DRI at Flawless Compounds →Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for FOXO4-DRI
Graded by what exists behind each claim.
Human clinical evidence
- No human trials: development stopped at preclinical, so the ceiling on any claim here is a rodent model — and these transfer poorly.
📊 Correlative data
- Very limited community use. Reported experience is unreliable here in a specific way: the claimed effect is invisible without tissue sampling — you cannot feel senescent cell clearance, so self-report has nothing real to anchor to.
- Beyond that the record is self-reported: community dosing logs are real information about tolerability and almost none about efficacy.
🧪 How the mechanism reads
- A peptide that disrupts the FOXO4–p53 interaction. In senescent cells, FOXO4 sequesters p53 in the nucleus, blocking the apoptosis p53 would otherwise trigger. Break that binding and p53 relocates to the mitochondria and the cell dies.
- The 2017 rodent paper reporting restored fur density, renal function and fitness in aged and progeroid mice is one of the more striking results in senolytic biology, and it is also essentially the entire evidence base.
- Peptides do not readily cross cell membranes, let alone reach the nucleus. The published construct used a retro-inverso D-amino-acid design specifically to address that — whether a research-market vial reproduces it is unverifiable, and a peptide that cannot get inside the cell cannot do any of this.
Why an empty tier is not a verdict → · What community dosing logs are worth →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What FOXO4-DRI actually does
FOXO4-DRI is the only compound in this Vault whose mechanism is to break a protein-protein interaction rather than to occupy a binding site, and that difference explains both why it is elegant and why it has not reached a person.
The problem it was designed against. A senescent cell is not merely an old cell. It has permanently exited the cell cycle, it resists apoptosis, and it secretes a mix of cytokines, proteases and growth factors — the senescence-associated secretory phenotype — that damages the tissue around it. The apoptosis resistance is the interesting part: a senescent cell carries the damage that should have triggered its own death, and something is preventing the trigger from firing Zhu 2015.
What is preventing it, in this particular account. In senescent cells the transcription factor FOXO4 is upregulated and binds p53, holding it in the nucleus — sequestered into nuclear foci and away from the mitochondrion. Mitochondrial p53 is what initiates intrinsic apoptosis. So a senescent cell has an activated death signal that is being physically detained. Break the FOXO4-p53 contact and p53 is released to do what it was already committed to doing, in cells that already carry the signal — which is why the killing is selective without needing a senescence-specific receptor Tripathi 2021.
How the peptide is built, and the name is the chemistry. DRI is D-retro-inverso. The sequence of the FOXO4 region that contacts p53 is written in reverse and every residue is the D-enantiomer. Reversing the backbone while inverting the chirality restores the side-chain topology of the original L-peptide, so the interaction surface is approximately preserved — while the backbone amide bonds are in a configuration mammalian proteases largely do not cleave. A D-retro-inverso peptide is a protease-resistant mimic of a protein surface, and it is one of the few general tricks for drugging an interaction that has no pocket.
The target has been resolved structurally since, and it sharpened the picture. Work modeling the FOXO4-TP53 interaction was used to design senolytic peptides for eliminating senescent cancer cells Le 2021, and precise disruption of the FOXO4-p53 complex has been used to develop a novel senolytic Tripathi 2021. Both of those are structure-led design papers rather than clinical ones, and that is exactly where this compound sits.
Cell, rodent, human — and where it stops
Step one, structure and cells: real, and the most solid part of the story. The FOXO4-p53 interaction has been modeled and used as a design target Le 2021, and precise disruption of the complex produces senolytic activity in culture Tripathi 2021.
Step two, mice, with a disease endpoint. A FOXO4 peptide targeting myofibroblasts ameliorated bleomycin-induced pulmonary fibrosis in mice through an extracellular-matrix-receptor pathway Han 2022. Bleomycin fibrosis is a real model with a real histological endpoint, and the choice of fibrosis is mechanistically apt: senescent myofibroblasts are a recognized driver of fibrotic disease, which is why the first human senolytic trial in any class was in idiopathic pulmonary fibrosis Justice 2019.
Step three, humans: there is no step three. No human has been dosed with FOXO4-DRI in a registered clinical trial. Not a phase 1, not a safety study, not a single-ascending-dose cohort. The comparison that makes this concrete is the other senolytic class: dasatinib and quercetin have a first-in-human study in idiopathic pulmonary fibrosis Justice 2019 and clinical work extending to diabetic kidney disease and to restoration of alpha-Klotho in mice and humans Zhu 2022. FOXO4-DRI has none of that, and the difference is not that the mechanism is worse — it is that one class is made of approved small molecules and the other is a large synthetic peptide.
Where the chain breaks, and the first one is decisive. (1) Delivery. FOXO4-DRI is a large, highly charged peptide that has to reach the nucleus of a target cell to do anything. Crossing a plasma membrane and then a nuclear envelope is a problem the D-retro-inverso trick does not solve; it solves protease resistance. Everything downstream of that failure is untested. (2) Mouse dosing in the published work is intraperitoneal or intravenous, not subcutaneous. (3) Senescent cells are heterogeneous — the FOXO4-p53 axis is one apoptosis-resistance route among several, so a senolytic built on it targets a subset. (4) The card's 6 to 12 hour half-life is a plasma figure and says nothing about how much reached a nucleus.
What would have to be true, and how you would know it was not
Three predictions. The honest framing first: there is no validated blood marker of cellular senescence, so anybody claiming to measure this compound working from a standard panel is overstating what the panel can do.
1. If senescent cells are being cleared, the secretory phenotype should fall — and that is measurable, imperfectly. The senescence-associated secretory phenotype is inflammatory. hs-CRP and TNF-alpha at baseline and at 12 weeks are the closest available proxies. Both are non-specific: an infection, a hard training block or an unrelated inflammatory condition moves them, so a single pair of values proves nothing and a trend across several time points off any acute illness proves slightly more.
2. The prediction that would be genuinely convincing borrows from the neighboring class. Senolytic therapy restored alpha-Klotho in mice and in humans in a published study Zhu 2022. That makes soluble Klotho the single best candidate read-out for any senolytic, because somebody has already shown it moves with senescent-cell clearance in people. Measuring it before and after would be the first evidence that FOXO4-DRI does anything in a human, and the assay exists.
3. The falsification test is a null result and it should be expected. Given the delivery problem, the most likely outcome of subcutaneous FOXO4-DRI is that nothing reaches a nucleus. So the prediction is: hs-CRP, TNF-alpha and any Klotho measurement remain flat, and a CMP and CBC show nothing. A person who runs those tests and finds no change has not failed. They have obtained the result the pharmacology predicts, and it is more information than any testimonial contains.
What nobody has tested yet
Four experiments nobody has run, and the first is a phase 1.
Nobody has run any human study. Not one. The comparison with dasatinib plus quercetin Justice 2019 Zhu 2022 is the useful one: a senolytic class with human data exists, and this compound is not in it. Everything anybody says about FOXO4-DRI in people is extrapolation from mice, and this page says so rather than dressing the mouse data as more than it is.
Nobody has published the biodistribution. The question that decides whether this compound can work is what fraction of a subcutaneous dose reaches the nucleus of a senescent cell in a peripheral tissue. A labeled-peptide biodistribution study with subcellular fractionation is the experiment. Its absence is the reason the mechanism cannot yet be evaluated in humans at all.
Nobody has tested it against dasatinib plus quercetin head-to-head. The two classes attack apoptosis resistance by different routes and there is no reason to assume they clear the same senescent populations. A comparison in the same animal model with tissue-level senescence quantification would say whether they are alternatives or complements — and would be far more informative than another single-agent study.
Nobody has resolved the safety question the mechanism raises. Senescence is a tumor-suppressive program: a cell that senesces instead of dividing is a cell that did not become a tumor. Clearing senescent cells systemically removes a brake as well as a burden Zhu 2015, and no study long enough to see the consequence has been run for any senolytic. This is the open question for the whole field, not just for this peptide.
FOXO4-DRI — its own safety story, not its class's
FOXO4-DRI has never been given to a human in a registered trial. Everything below is reasoning from mechanism, and it is labeled as such because the class block above cannot say the most important thing about this compound: that its safety profile does not exist.
The mechanism-derived concern is p53 itself. The compound works by releasing p53 from sequestration Tripathi 2021. p53 is not a senescence protein — it is the central node of the DNA damage response in every nucleated cell. A systemic agent that shifts p53 localization is not acting only on senescent cells; it is acting where p53 and FOXO4 are both present, and nobody has mapped where that is in a person.
The second concern is that senescence is protective. Removing senescent cells removes a source of inflammation and a brake on malignant transformation at the same time Zhu 2015. Whether the net is favorable over years is the open question for every senolytic, and it is unanswered.
The third is wound healing and fibrosis, cutting both ways. Transient senescence is part of normal repair. The mouse fibrosis result Han 2022 shows the peptide acting on myofibroblasts — the same cells that close a wound. A senolytic given around surgery or injury is interfering with a program that has a job.
Peptide-specific problems are large here. This is a long synthetic peptide made entirely of D-amino acids in reversed sequence. Verifying that a vendor has produced the correct D-retro-inverso sequence rather than an L-peptide, a partial sequence, or a scrambled one requires analysis almost nobody performs, and an L-form of the same sequence would have the same mass and different behavior. Immunogenicity of a large foreign peptide is a separate and equally uncharacterized risk.
What this page will not do. Print a dose, a route or a cycle. There is no human dose because there has been no human study. The mechanism is one of the most interesting in this Vault and the clinical evidence is zero, and holding both of those in view at once is the entire point of the page.
Sources read for this page
- Tripathi U, et al. Development of a novel senolytic by precise disruption of FOXO4-p53 complex. EBioMedicine 2021 · PMID 34768086
- Le HH, et al. Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells. EBioMedicine 2021 · PMID 34689087
- Han X, et al. FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway. Journal of Cellular and Molecular Medicine 2022 · PMID 35510614
FOXO4-DRI — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- The mechanism is deliberate cell death. FOXO4 holds p53 in the nucleus of senescent cells and keeps them alive; a D-retro-inverso peptide built to disrupt that interaction releases p53 and the cell kills itself. This is not a signaling peptide with a gentle effect — it is a molecule designed to make cells die, and the safety of it rests entirely on which cells.
- So every predictable harm is a selectivity question. If selectivity is imperfect at whatever exposure a person actually achieves, p53-driven apoptosis is being induced in cells that were doing their job. There is no way to tell from the outside which of those is happening, and no symptom that would announce it early.
- The D-retro-inverso design exists to resist proteolysis, which means a longer-lived molecule than a natural peptide. That is an advantage for the intended effect and an equal disadvantage for anything unintended — there is no quick way to take it back.
What has actually been reported
- Nothing in humans. No clinical trial, no published human pharmacokinetics, no case series. What circulates is anecdote, and the published work is mouse work.
How to reduce the risk
Same mechanism as the prediction.
- The honest position is that there is no mitigation that makes an uncharacterized apoptosis-inducing peptide a measured risk. Pretending otherwise would be the boilerplate failure this file exists to avoid, in the other direction.
- What can be said: take baseline bloods so a change is detectable, run it alone rather than in a senolytic stack, tell a clinician, and treat any protocol you find online as somebody's guess rather than a dosing standard.
- Decide the endpoint and the stop date before you start. With a compound this unevidenced, an unfalsifiable endpoint guarantees you will conclude it worked whatever happened.
What it does to your bloodwork
A fact about the assay.
- There is no assay for the compound and no orderable test for senescent-cell burden — the ones used in research are not clinical tests.
- What is available is a baseline: full blood count, liver and kidney panel, and an inflammatory marker. None of them will tell you it is working. All of them make a later change interpretable instead of a guess.
What it overlaps with
- Stacking it with dasatinib and quercetin is two senolytics aimed at the same cells by different routes, on a schedule established for neither. If something changes, you will not know which one did it — and with an evidence base this thin, attribution is the only value your own experiment has.
Don't run this if
- Active or recent malignancy, or any current cancer treatment. p53 signaling is precisely what several oncology drugs are manipulating, and adding an uncharacterized apoptosis-inducing peptide to that is not a stack anyone can reason about.
- Pregnancy, breastfeeding or trying to conceive.
- Any immunosuppressed state, where clearing cells and provoking an inflammatory clean-up are both harder to handle.
The honest unknown
- Essentially all of it: dose-response, distribution, half-life in a person, how selective the peptide really is at achievable exposures, what happens in tissue carrying a heavy senescent-cell burden when a lot of it dies at once, and whether human immune clearance handles the debris the way a mouse's does.
- What is in the vial. This is not sold as a medicine anywhere. No one is verifying identity, sequence or purity, and a retro-inverso peptide is not something a buyer can check.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
FOXO4-DRI — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What FOXO4-DRI moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
Where these work, systemic inflammation is the plausible readout.
What to do: hs-CRP is cheap and moves. Baseline and 12 weeks. - HbA1c (Hemoglobin A1c) — ↓ expected to fall
Improved mitochondrial and metabolic function should show here if the effect is real at all.
What to do: The honest use of these markers is as a falsification test: if nothing moves in 12 weeks, the compound is not doing much for you. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Liver and kidney function — the standard baseline for anything run long term.
What to do: Twice a year is enough on a stable protocol.
This class is where honest expectation-setting matters most: the markers above are how you find out whether anything happened, and for most of these compounds that question is genuinely open.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — FOXO4-DRI in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside FOXO4-DRI
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
FOXO4-DRI — frequently asked questions
What is FOXO4-DRI?
FOXO4-DRI (FOXO4-D-Retro-Inverso peptide) is a longevity & bioregulators research compound. Senolytic — disrupts the FOXO4–p53 interaction so senescent 'zombie' cells self-destruct, clearing them from tissue.
Is the full FOXO4-DRI protocol on this page?
The reported research dose is on this page, along with how FOXO4-DRI works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of FOXO4-DRI?
FOXO4-DRI has an approximate half-life of ~6-12 hrs, which is part of what determines how often it's dosed.
What's the evidence behind FOXO4-DRI?
Current evidence level: Animal. FOXO4-DRI is offered for research purposes only and is not an approved medicine.
FOXO4-DRI inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What FOXO4-DRI is used for
FOXO4-DRI appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
FOXO4-DRI is the senolytic arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.